Hardik Shah
2026.05.12 11:07

๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $Viking Therap(VKTX.US) Viking Therapeutics Reports Phase 2 Oral VK2735 Obesity Data

๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:

โžค Oral ๐•๐Š๐Ÿ๐Ÿ•๐Ÿ‘๐Ÿ“ achieved up to ๐Ÿ๐Ÿ.๐Ÿ% weight loss in ๐Ÿ๐Ÿ‘ weeks.

โžค Placebo group recorded ๐Ÿ.๐Ÿ‘% average weight reduction.

โžค Trial enrolled ๐Ÿ๐Ÿ–๐ŸŽ adults with obesity or overweight conditions.

โžค Weight loss began by ๐ฐ๐ž๐ž๐ค ๐Ÿ and continued without plateauing.

โžค Up to ๐Ÿ—๐Ÿ•% of participants achieved at least ๐Ÿ“% weight loss.

โžค Treatment targets both ๐†๐‹๐-๐Ÿ and ๐†๐ˆ๐ receptors.

โžค Viking plans to launch ๐๐ก๐š๐ฌ๐ž ๐Ÿ‘ trials for oral VK2735 this year.

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.